Clinical evaluation of PF614, a novel TAAP prodrug of oxycodone, versus OxyContin in a multi‐ascending dose study with a bioequivalence arm in healthy volunteers
Abstract PF614, a trypsin‐activated abuse protection oxycodone prodrug designed to reduce recreational drug abuse, was compared to OxyContin for safety and pharmacokinetics (PKs) of plasma oxycodone following oral administration. This study was a two‐part design including a multi‐ascending dose (par...
Saved in:
Main Authors: | D. Lynn Kirkpatrick (Author), Cari Evans (Author), Linda A. Pestano (Author), Jeffrey Millard (Author), Matthew Johnston (Author), Emily Mick (Author), William K. Schmidt (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2024-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Monitoring of Internet Forums to Evaluate Reactions to the Introduction of Reformulated OxyContin to Deter Abuse
by: McNaughton, Emily C, et al.
Published: (2014) -
A US Retrospective Claims Analysis Comparing Healthcare Costs of Patients Transitioning from Immediate-Release Oxycodone to Two Different Formulations of Extended-Release Oxycodone: Xtampza ER or OxyContin
by: Olatoke O, et al.
Published: (2022) -
High-dose OxyContin to treat pain associated with bone metastasis in patients with small-cell lung cancer: a case study report
by: Zhou T, et al.
Published: (2016) -
Comparing the effects of decreasing prescription opioid shipments and the release of an abuse deterrent OxyContin formulation on opioid overdose fatalities in WV: an interrupted time series study
by: Eric W. Lundstrom, et al.
Published: (2024) -
Epidural Oxycodone for Acute Pain
by: Panu Piirainen, et al.
Published: (2022)